S100A12 Human ELISA

Cat. No.	Size	Price
RD191221200R	96 wells (1 kit)	$711

Technical Data

Notice

For processing the stool samples we recommend using BioVendor Extraction Buffer. The reagent is not included and can be ordered separately (Cat. No.: C005821, 100 ml).

Please find the protocol for preparation and analysis of stool extracts in Docs.

Type

Sandwich ELISA, Biotin-labelled antibody

Applications

Stool, Serum, Bronchoalveolar lavage

Sample Requirements

Serum: 5 µl/well
For processing the stool samples we recommend using BioVendor Extraction Buffer. The reagent is not included and can be ordered separately (Cat. No.: C005821, 100 ml).

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

0.063–4 ng/ml

Limit of Detection

0.02 ng/ml

Intra-assay (Within-Run)

n = 8; CV = 3.6 %

Inter-assay (Run-to-Run)

n = 6; CV = 4.7 %

Spiking Recovery

Serum: 105.7 %
Stool: 96.1 %
BALF: 99.7 %

Dilution Linearity

Serum: 98.7 %
Stool: 93.8 %
BALF: 92.1 %

Crossreactivity

bovine Non-detectable
cat Non-detectable
dog Non-detectable
goat Non-detectable
hamster Non-detectable
horse Non-detectable
chicken Non-detectable
monkey Non-detectable
mouse Non-detectable
rabbit Non-detectable
rat Non-detectable
sheep Non-detectable
human Yes
pig Yes

Summary

Features

It is intended for research use only
The total assay time is less than 3.5 hours
The kit measures S100A12 in serum, bronchoalveolar lavage and stool extract
For protocol for preparation of stool extracts and other details, please contact us at info@biovendor.com
Assay format is 96 wells
Quality Controls are human serum based
Standard is recombinant protein based
Components of the kit are provided ready to use, concentrated or lyophilized

Research topic

Immune Response, Infection and Inflammation, Inflammatory bowel disease, Lipoprotein metabolism, Neural tissue markers, Oncology, Pulmonary diseases, Renal disease

Summary

S100A12 (EN-RAGE, calgranulin) is a member of the S100 protein family, which, in humans, consists of twenty five EF-hand (alpha helix-loop-alpha helix), calcium-binding proteins, of which the vast majority is in homodimer, heterodimer or more complex forms. Mature S100A12 consists of 91 amino acids (Mw 10.4 kDa); it is predominantly expressed and secreted by neutrophil granulocytes and to a lower extent, it was found in monocytes. Hofmann et al. (1999) reported that RAGE is a central cell surface receptor for S100A12, which they referred to as EN-RAGE (Extracellular Newly identified RAGE-binding protein), and related members of the S100/calgranulin superfamily. Interaction of EN-RAGE (S100A12) with cellular RAGE on endothelium, mononuclear phagocytes, and lymphocytes triggered cellular activation, with generation of key proinflammatory mediators. In murine models, blockade of EN-RAGE/RAGE quenched delayed-type hypersensitivity and inflammatory colitis by arresting activation of central signaling pathways and expression of inflammatory gene mediators. With regard to its inflammatory properties, S100A12 was already described as a promising marker for many diseases in humans such as neurodegenerative diseases, atherosclerosis, cancerogenesis, osteoarthritis, familial mediterranean fever and idiopathic pulmonary fibrosis. Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients. S100A12 and its receptor RAGE are found at high concentrations in pulmonary tissue and bronchoalveolar lavage fluid in acute lung injury. S100A12 expression reflects neutrophil activation during lung inflammation. Faecal S100A12 is a novel non-invasive marker distinguishing inflammatory bowel disease (IBD) from irritable bowel syndrome (IBS). Furthermore, S100A12 reflects inflammatory activity of chronic IBD. As a marker of neutrophil activation, faecal S100A12 may significantly improve the arsenal of non-invasive biomarkers of intestinal inflammation.

Product References (2)

References

Navrátilová A, Bečvář V, Baloun J, Damgaard D, Nielsen CH, Veigl D, Pavelka K, Vencovský J, Šenolt L, Andrés Cerezo L. S100A11 (calgizzarin) is released via NETosis in rheumatoid arthritis (RA) and stimulates IL-6 and TNF secretion by neutrophils. Sci Rep. 2021 Mar 16;11(1):6063. doi: 10.1038/s41598-021-85561-3. PubMed PMID: 33727634. PubMed CentralPMCID: PMC7966750. See more on PubMed
Máca J, Peteja M, Reimer P, Jor O, Šeděnková V, Panáčková L, Ihnát P, Burda M, Ševčík P. Surgical injury: comparing open surgery and laparoscopy by markers of tissue damage. Ther Clin Risk Manag. 2018 May 30;14:999-1006. doi: 10.2147/TCRM.S153359. eCollection 2018. PubMed PMID: 29881282. PubMed CentralPMCID: PMC5985784. See more on PubMed

Summary References (15)

References to S100A12

Goyette J, Yan WX, Yamen E, Chung YM, Lim SY, Hsu K, Rahimi F, Di Girolamo N, Song C, Jessup W, Kockx M, Bobryshev YV, Freedman SB, Geczy CL. Pleiotropic roles of S100A12 in coronary atherosclerotic plaque formation and rupture. J Immunol. 2009 Jul 1;183 (1):593-603
Hofmann Bowman M, Wilk J, Heydemann A, Kim G, Rehman J, Lodato JA, Raman J, McNally EM. S100A12 mediates aortic wall remodeling and aortic aneurysm. Circ Res. 2010 Jan 8;106 (1):145-54
Kallinich T, Wittkowski H, Keitzer R, Roth J, Foell D. Neutrophil-derived S100A12 as novel biomarker of inflammation in familial Mediterranean fever. Ann Rheum Dis. 2010 Apr;69 (4):677-82
Kalousova M, Kubena AA, Benakova H, Dusilova-Sulkova S, Tesar V, Zima T. EN-RAGE (extracellular newly identified receptor for advanced glycation end-products binding protein) and mortality of long-term hemodialysis patients: A prospective observational cohort study. Clin Biochem. 2012 May;45 (7-8):556-60
Kikkawa T, Sato N, Kojika M, Takahashi G, Aoki K, Hoshikawa K, Akitomi S, Shozushima T, Suzuki K, Wakabayashi G, Endo S. Significance of measuring S100A12 and sRAGE in the serum of sepsis patients with postoperative acute lung injury. Dig Surg. 2010;27 (4):307-12
Kosaki A, Hasegawa T, Kimura T, Iida K, Hitomi J, Matsubara H, Mori Y, Okigaki M, Toyoda N, Masaki H, Inoue-Shibata M, Nishikawa M, Iwasaka T. Increased plasma S100A12 (EN-RAGE) levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2004 Nov;89 (11):5423-8
Mahajan N, Malik N, Bahl A, Dhawan V. Receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease. Atherosclerosis. 2009 Dec;207 (2):597-602
Miniati M, Monti S, Basta G, Cocci F, Fornai E, Bottai M. Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study. Respir Res. 2011;12:37
Mori Y, Kosaki A, Kishimoto N, Kimura T, Iida K, Fukui M, Nakajima F, Nagahara M, Urakami M, Iwasaka T, Matsubara H. Increased plasma S100A12 (EN-RAGE) levels in hemodialysis patients with atherosclerosis. Am J Nephrol. 2009;29 (1):18-24
Myles A, Viswanath V, Singh YP, Aggarwal A. Soluble receptor for advanced glycation endproducts is decreased in patients with juvenile idiopathic arthritis (ERA category) and inversely correlates with disease activity and S100A12 levels. J Rheumatol. 2011 Sep;38 (9):1994-9
Nakashima M, Sakai T, Hiraiwa H, Hamada T, Omachi T, Ono Y, Inukai N, Ishizuka S, Matsukawa T, Oda T, Takamatsu A, Yamashita S, Ishiguro N. Role of S100A12 in the pathogenesis of osteoarthritis. Biochem Biophys Res Commun. 2012 Jun 8;422 (3):508-14
Shiotsu Y, Mori Y, Nishimura M, Sakoda C, Tokoro T, Hatta T, Maki N, Iida K, Iwamoto N, Ono T, Matsuoka E, Kishimoto N, Tamagaki K, Matsubara H, Kosaki A. Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients. Clin J Am Soc Nephrol. 2011 Apr;6 (4):718-23
Shiotsu Y, Mori Y, Nishimura M, Sakoda C, Tokoro T, Hatta T, Maki N, Iida K, Iwamoto N, Ono T, Matsuoka E, Kishimoto N, Tamagaki K, Matsubara H, Kosaki A. Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients. Clin J Am Soc Nephrol. 2011 Apr;6 (4):718-23
Thierolf M, Hagmann ML, Pfeffer M, Berntenis N, Wild N, Roessler M, Palme S, Karl J, Bodenmuller H, Ruschoff J, Rossol S, Rohr G, Rosch W, Friess H, Eickhoff A, Jauch KW, Langen H, Zolg W, Tacke M. Towards a comprehensive proteome of normal and malignant human colon tissue by 2-D-LC-ESI-MS and 2-DE proteomics and identification of S100A12 as potential cancer biomarker. Proteomics Clin Appl. 2008 Jan;2 (1):11-22
Wittkowski H, Frosch M, Wulffraat N, Goldbach-Mansky R, Kallinich T, Kuemmerle-Deschner J, Fruhwald MC, Dassmann S, Pham TH, Roth J, Foell D. S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of u

Docs

Instructions for Use (RUO)

Application protocol
Instructions for Use (RUO)

Safety Information (RUO)

MSDS (RUO)
MSDS (RUO)